Cobalis Corp.'s PreHistin(R) Allergy Defense Formula Wins 2011 Best New Product Award at ECRM Allergy Show

IRVINE, Calif., March 10, 2011 /PRNewswire/ -- Cobalis Corp.'s (Pink Sheets: CLSC) http://www.prehistin.com/ [PreHistin® Allergy Defense Formula], the first ever pre-histamine, has taken the coveted 2011 Best New Product Award at the ECRM Cough, Cold and Allergy show held in Orlando, FL, February 28-March 3. PreHistin® regulates overproduction of the key allergen antibody IgE to restore a normal response to both seasonal and year-round allergens, which according to leading US allergist and clinical researcher Dr. Paul H. Ratner, MD is “no allergic response at all!”

“We are very proud that PreHistin® was selected by the country’s leading retail and pharmacy buyers as ‘Best New Product of the Year’ out of a field of thousands of products. In introducing PreHistin® as the world’s first PRE-histamine, we have literally created an entirely new category in allergy care, as well as offering the more than 60 million Americans who suffer from seasonal and year-round allergies the first major new option available in years the opportunity to regulate allergen antibody IgE levels to restore a normal, non-reactive response to allergens, as opposed to treating symptoms after an allergic reaction has started. We thank the retailers and distributors who attended this show for awarding us this great honor and recognition,” said Marty Marion, CEO of Cobalis Corp.

PreHistin® is now on shelves at one of the nation’s two largest drugstore chains, and is expected to be on pharmacy and grocery shelves across the country very quickly. Indoor and outdoor allergy sufferers, who need relief seasonally or year-round, can feel the benefits of PreHistin® in as little as a few weeks of regular use. The all-natural formula of PreHistin® is a lozenge dissolved under the tongue and then swallowed twice a day during allergy season, or year-round for those who suffer from indoor allergens like dust, mold and pet dander.

“I recommend that all of my patients who suffer from allergies use PreHistin®,” said allergist Dr. Paul Ratner. “Not only is the product safe but it is extremely effective, completely non-drowsy, and has no side effects.”

Readers who are interested in more information should visit www.prehistin.com. To arrange a media interview with Dr. Paul Ratner please contact Nancy Trent or Pam Wadler at 212-966-0024 or send an email to pam@trentandcompany.com.

ABOUT PREHISTIN® ALLERGY DEFENSE FORMULA

PreHistin® Allergy Defense Formula is a unique, patented cobalamin complex product that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine which is linked to the onset of symptoms such as sneezing, itchy watery eyes, runny nose and nasal congestion. PreHistin® is a cherry-flavored lozenge that is dissolved under the tongue and then swallowed twice a day, usually starting before the allergy season, or taken daily for those suffering from year-round allergies. PreHistin® has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications. In clinical trials on thousands of allergy sufferers, PreHistin® was shown to be safe and effective in reducing nasal symptoms.

ABOUT COBALIS CORP.PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, “The World’s First Pre-Histamine”, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is now available without prescription for both long-term and daily use.

For PreHistin® product information please visit www.PreHistin.com or call toll free

1-877-4POLLEN (1-877-476-5536). For additional company information please visit the corporate website at www.Cobalis.com.

CONTACT

Cobalis Corp.

949-260-0123

Chas Radovich, President

Martin Marion, CEO

info@cobalis.com

SOURCE Cobalis Corp.

MORE ON THIS TOPIC